Table 1.
Proportions (in %) of Vδ1 γδ T cells of all γδ T cells in tumors positive or negative for MICA/B and of γδT cells (in %) of CD3+ T cells
Tumor | mAb 6D4 | % γδT cells | % Vδ1 γδ cells |
---|---|---|---|
CT-001-97 | + | 3 | 80 |
CT-046-98 | + | 15 | 46 |
CT-183-73 | + | 7 | 67 |
BT-046-99 | − | 2 | 25 |
BT-086-22 | − | 3 | 40 |
BT-086-38 | − | 2 | 21 |
BT-140-73 | − | 3 | 9 |
BT-183-26 | − | 1 | 10 |
BT-183-43 | − | 4 | 20 |
BT-183-76 | + | 4 | 51 |
BT-238-29 | + | 16 | 100 |
LT-086-36 | − | 2 | 2 |
LT-086-49 | − | 2 | 2 |
LT-140-26 | + | 2 | 60 |
LT-140-66 | + | 1 | 55 |
OT-183-83 | + | 2 | 80 |
OT-183-93 | + | 2 | 51 |
OT-238-01 | + | 4 | 35 |
PT-140-63 | + | 6 | 65 |
PT-183-87 | − | 2 | 20 |
PT-391-97 | + | 10 | 55 |
RT-046-29 | + | 4 | 70 |
Representative examples for tumor cell suspensions positive or negative for binding of mAb 6D4 are shown in Fig. 1. The frequencies of Vδ1 γδ T cells of all γδ T cells in MICA/B+ tumors were statistically significantly higher (P < 0.0001, Wilcoxon rank-sum test) as compared with the tumors that were MICA/B−. All samples were positive for binding of mAb W6/32 (anti-HLA-A, -B, and -C). Examined were carcinomas of colon (CT), breast (BT), lung (LT), ovary (OT), prostate (PT), and renal cell (RT).